

September 11, 2017

**BSE Limited**  
**Corporate Relationship Department**  
**1st floor, New Trading Ring**  
**Rotunda Building, P J Towers**  
**Dalal Street, Fort Mumbai - 400 001**

Dear Sir,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This letter is being issued as authorised by the Interim Resolution Professional (IRP).

In pursuance of our earlier communication dated August 22,2017 informing about the initiation of the Corporate Insolvency Resolution Process against Orchid Pharma Limited ("Company"),we would like to further inform you that, Mr.Rajasekaran (IP Registration no: IBBI/IPA-003/IP-N00053/2017-18/10493) has been appointed as the Interim Resolution Professional and the management of the affairs of the Company now vests with him as per Section 17 of the Insolvency and Bankruptcy Code,2016 read along with the regulations framed thereunder ("IBC").

Since the IRP has been appointed recently by the Hon'ble National Company Law Tribunal, (NCLT), Chennai Bench and is in the process of collating claims and reviewing the requisite financial and other relevant records of the Company, we would not be in a position to submit the Quarterly Financial statements (for Q1 2017-18) to the Stock exchanges on or before September 14, 2017 as per SEBI circular CIR/CFD/FAC/62/2016 dated July 05, 2016.

In view of the above, we wish to inform you that the IRP shall consider the Quarterly financial statements in due course and the date of such consideration shall be duly intimated.

The above may be treated as a disclosure pursuant to Regulation 30 of the LODR Regulations.





Thanking you,

Yours Faithfully,

L Chandrasekar

Executive VP – Finance & Secretary

**CC: Mr.Rajasekaran**

**Interim Resolution Professional**

**(IP Registration no: IBBI/IPA-003/IP-N00053/2017-18/10493)**

**Orchid Pharma Limited**